Plasma membrane calcium ATPases (PMCAs) as potential targets for the treatment of essential hypertension. by Little, Robert et al.
Associate Editor: Simon Kennedy
Plasma membrane calcium ATPases (PMCAs) as potential targets for the
treatment of essential hypertension
Robert Little a, Elizabeth J. Cartwright a, Ludwig Neyses a, Clare Austin b,⁎
a The Institute of Cardiovascular Sciences, The University of Manchester, UK
b Faculty of Health and Social Care, Edge Hill University, UK
a b s t r a c ta r t i c l e i n f o
Available online 25 January 2016 The incidence of hypertension, the major modiﬁable risk factor for cardiovascular disease, is increasing. Thus,
there is a pressing need for the development of new andmore effective strategies to prevent and treat hyperten-
sion. Development of these relies on a continued evolution of our understanding of the mechanisms which con-
trol blood pressure (BP).
Resistance arteries are important in the regulation of total peripheral resistance andBP; changes in their structure
and function are strongly associated with hypertension. Anti-hypertensives which both reduce BP and reverse
changes in resistance arterial structure reduce cardiovascular risk more than therapies which reduce BP alone.
Hence, identiﬁcation of novel potential vascular targets which modify BP is important.
Hypertension is a multifactorial disorder which may include a genetic component. Genome wide association
studies have identiﬁed ATP2B1, encoding the calcium pump plasma membrane calcium ATPase 1 (PMCA1), as
having a strong association with BP and hypertension. Knockdown or reduced PMCA1 expression in mice has
conﬁrmed a physiological role for PMCA1 in BP and resistance arterial regulation. Altered expression or inhibition
of PMCA4 has also been shown tomodulate these parameters. Themechanismswhereby PMCA1 and 4 canmod-
ulate vascular function remain to be fully elucidated but may involve regulation of intracellular calcium homeo-
stasis and/or comprise a structural role. However, clear physiological links between PMCA and BP, coupled with
experimental studies directly linking PMCA1 and 4 to changes in BP and arterial function, suggest that they may
be important targets for the development of new pharmacological modulators of BP.
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1. Introduction
Hypertension is a major public health issue and is responsible for
considerable morbidity and mortality. As such, there is a continued
need for the identiﬁcation of new targets for more effective treatments
for high blood pressure (BP). Changes in the structure and function of
resistance arteries play a key role in the development of hypertension
(Heagerty et al., 2010; Rizzoni & Agabiti-Rosei, 2012).
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Plasma membrane calcium ATPases (PMCAs) are ATP driven
calmodulin-dependent pumps. PMCAs extrude Ca2+ ions from the cell
and may thus contribute to the regulation of global, and sub-cellular,
concentrations of intracellular free Ca2+ ([Ca2+]i) (Karaki et al., 1997;
Carafoli et al., 2001; Cartwright et al., 2011). However, it is now evident
that PMCAs also have important roles as scaffold proteinswhereby they
may play a key role in signal transduction (Schuh et al., 2001; Williams
et al., 2006; Cartwright et al., 2007; Strehler, 2015). Mammalian PMCAs
belong to a multigene family of four different genes (ATP2B1–4 in
humans)which encode respectively for PMCA proteins 1–4. The protein
expression of PMCA2 and 3 is limited, principally to neuronal-type cells,
however, PMCA1 and 4 are expressed throughout the body (Carafoli,
1991; Keeton et al., 1993; Street et al., 1998; Okunade et al., 2004).
In this review we focus on essential (primary) hypertension and
provide an overview of current knowledge relating to the regulatory ef-
fects of PMCAs on the resistance vasculature and effects on BP. Based on
this we present an argument to support PMCA-mediated pathways as
promising new targets for the treatment of hypertension. Whilst
we recognise the importance of cardiac function in relation to BP control
such a broad topic is beyond the scope of this review. PMCAs
provide only a minor contribution to expulsion of total Ca2+ from
cardiomyocytes (Bers, 2000). However, ongoing studies seek to clearly
deﬁne the role of PMCAs in other cardiac cell types and under patholog-
ical conditions, and we direct interested readers to some of the publica-
tions in this area (Oceandy et al., 2007; Mackiewicz et al., 2009; Wu
et al., 2009; Chen et al., 2010; Cartwright et al., 2011).
2. Hypertension
2.1. A global clinical issue
Hypertension is the major modiﬁable risk factor for cardiovascular
disease, themost common cause of morbidity andmortality worldwide
(Whelton, 1994; Wilson, 1994; Yusuf et al., 2001; Ezzati et al., 2002;
WHO, 2013). Chronically elevated BP potentiates the risk of stroke,
heart and renal failure and cardiac events (Whelton, 1994; Kearney
et al., 2005). Since 2010 it has been estimated that hypertension con-
tributes tomore than9.4million deaths and 7% of globalDALYs (Disabil-
ity-Adjusted Life Burden as a representation of the numbers of years lost
due to ill health or early death) annually, and was the single greatest
risk factor globally for these (Lim et al., 2012). It is estimated that 30–
40% of the world's population suffers from hypertension, although the
true incidence may be higher as elevated BP can remain asymptomatic
(Lawes et al., 2008; Roger et al., 2012; Mancia et al., 2013). The preva-
lence of hypertension increases with ageing; whilst it has been estimat-
ed that fewer than 10% of people under the age of 40may have elevated
BP, more than 60% of people aged over 70 require clinical intervention
for hypertension (Lloyd-Jones et al., 2005; Egan et al., 2010). Theworld's
population is ageing; the number of people over 60 years of age has
doubled since 1980 and is predicted to reach 2 billion by 2050 (WHO,
2014). A consequence of this is an increased number of people living
with hypertension and associated complications. Indeed, it has been es-
timated that between 1980 and 2008 the global number of people with
hypertension rose from 600 million to almost 1 billion (Danaei et al.,
2011), and that this number is continuing to rise (Fields et al., 2004;
Heidenreich et al., 2011).
The relative risk for cardiovascular disease is directly associatedwith
the absolute level of BP (Whitworth, 2003),with the risk of cardiovascu-
lar disease having been reported to double for each 20/10mmHg incre-
ment increase in BP (Chobanian et al., 2003). Treatments for
hypertension often involve a combination of lifestyle changes and phar-
macological intervention and, when successful, can have a highly posi-
tive impact on cardiovascular risk. Data from randomised controlled
trials and prospective studies have shown that lowering BP by even 5–
6mmHg is associatedwith approximately 20% and 40% reduction in ad-
verse coronary events and stroke respectively (Lewington et al., 2002;
Law et al., 2009). However, some current therapeutic strategies appear
to be of limited effectiveness for an increasing number of patients, with
multidrug resistance or poor adherence to treatment regimes being re-
ported (Morisky et al., 2008; Tomaszewski et al., 2014; Vega &
Bisognano, 2014; Vongpatanasin, 2014; Sakhuja et al., 2015). Resistant
hypertension is associatedwith increased target organ damage and car-
diovascular complications (Muiesan et al., 2013). As such, and alongside
likely increasing demand from an increasingly ageing global population,
there is a pressing need for development of new and more effective
strategies to prevent and treat hypertension.Development of such strat-
egies relies on a continued evolution of our understanding of themech-
anisms which control BP.
2.2. Factors contributing to the development of hypertension
Although high BP may be attributable to clear medical conditions,
termed secondary hypertension, it remains that no clear cause is evi-
dent for around 90% of people who have high BP (Lloyd-Jones et al.,
2005; Messerli et al., 2007). This type of hypertension is called primary
or essential hypertension. It has long been accepted that BP is a quanti-
tative trait with continuous variation, pointing to multiple factors
inﬂuencing the level of human BP (Pickering, 1972; Deng, 2007). It is
clear that lifestyle can have a very important impact on hypertension
and cardiovascular health, and, as there are numerous publications in
this area, this will not be considered further in this review. However,
it is also apparent that BP has a heritable component of about 15–60%;
such a range being dependent on whether in-clinic or ambulatory mea-
sures of BP are studied (Mongeau, 1989; Kotchen et al., 2000; Kupper
et al., 2005; Zuk et al., 2012). Whilst, from a pharmacological point of
view, it is important to understand the underlying molecular mecha-
nisms which contribute to the development of essential hypertension,
this is confounded by the complex nature in which potentially multiple
susceptibility genes are themselves modulated by environmental fac-
tors and interactions with other genetic loci (O'Shaughnessy, 2001).
Recent advances in genetic sequencing technology have enabled in-
vestigations to determinewhether speciﬁc genetic factors can confer sus-
ceptibility to disease. Genome wide association studies (GWAS) in
multiple different ethnic populations have revealed at least 52distinct ge-
netic variants with signiﬁcant association to BP and/or hypertension
(McCarthy et al., 2014; Tragante et al., 2014). Each individual variant ap-
pears to only have a modest direct effect on BP (less than 1mmHg per al-
lele for systolic pressure), so, even collectively, these loci may only
provide a minor contribution to the known percentage heritability of BP
(Johnson et al., 2011; McCarthy et al., 2014). Therefore, it appears more
genes, pathways or gene–environment interactions remain to be eluci-
dated to more fully describe the genetic basis of essential hypertension.
Whilst such associations can highlight new targets for possible regulation
of BP, physiologically testing the function of genes within target loci is a
key requirement for conﬁrming whether a gene within, or part of, a loci
of association is indeed part of a pathway which can inﬂuence BP.
3. Resistance arteries and essential hypertension
BP is the product of cardiac output and total peripheral resistance.
Although cardiac output and sympathetic activity may be elevated in
the early stages of hypertension, increased peripheral resistance is the
main driver for chronically elevated BP (Heagerty et al., 2010). Resis-
tance to ﬂow can be inﬂuenced by blood viscosity, vessel length and
vessel diameter, with resistance being inversely proportional to the
fourth power of the vessel's radius (Poiseuille's law) (Badeer, 2001;
Sriram et al., 2014). Small arteries which provide the greatest percent-
age contribution to peripheral resistance have been termed resistance
arteries, and are deﬁned as pre-capillary vessels composed of a relative-
ly thick media layer and having internal diameter of approximately
100–300 μm (Mulvany & Aalkjaer, 1990; Korsgaard et al., 1993;
Christensen & Mulvany, 2001; Heagerty et al., 2010). As resistance
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arteries play a key role in regulating peripheral vascular resistance, the
structure and contractility of these vessels are crucially important fac-
tors in determining and regulating BP. Importantly, changes in both
the structure and function of resistance arteries are believed to play an
essential role in the development and progression of hypertension
(Heagerty et al., 2010; Rizzoni & Agabiti-Rosei, 2012).
3.1. Resistance artery structure and hypertension
It iswell established that structural changes in resistance arteries are
associated with chronically elevated BP (Heagerty et al., 2010; Rizzoni
et al., 2011; Mulvany, 2012). There is now signiﬁcant evidence to
support the notion that high BP is associated with a remodelling of
resistance arteries such that there is a thickening of the medial layer
of the arterial wall of resistance arteries, a reduced lumen diameter
and thus an increased media to lumen ratio (Korsgaard et al., 1993;
Martinez-Lemus et al., 2009; Rizzoni & Agabiti-Rosei, 2012; Renna
et al., 2013). Although growth may be evident in certain pathologies
and in advanced hypertension (Rizzoni et al., 1996), there is now a
wealth of evidence to suggest that inward remodelling of resistance ar-
teries with no signiﬁcant change in cross sectional area, termed eutro-
phic remodelling, is a key feature of essential hypertension, and
underpins elevated peripheral resistance (Heagerty et al., 1993; Izzard
et al., 2005; Heerkens et al., 2006; Staiculescu et al., 2013). Eutrophic
remodelling of resistance arteries is proposed to be a consequence of re-
alignment and potentially closer associations between vascular smooth
muscle cells (VSMCs) of the arterial wall, and not hypertrophy and/or
hyperplasia of VSMCs, generating a detectable narrowing in lumen
diameter of the vessel (Heagerty et al., 2010), Fig. 1.
There are now numerous studies which support the notion that
changes in small artery structure have strong prognostic signiﬁcance
in hypertensive patients, over and above all other known cardiovascular
risk factors (Rizzoni et al., 2003; De Ciuceis et al., 2007; Mathiassen,
Buus, et al., 2007b). Understanding the mechanisms which may modu-
late resistance arterial eutrophic remodelling is thus important, but
these remain poorly understood. Prolonged vasoconstriction appears
important, which, in itself may modulate re-organisation via the activi-
ties of cross-linking enzymes such as tissue-type transglutaminase and/
or integrins (Bakker et al., 2002, 2005;Heerkens et al., 2006). It has been
proposed that initial eutrophic remodelling may be an energetically
favourable adaptivemechanism to normalisewall stress tomaintain ad-
equate blood ﬂow, whilst a growth response, whichmay be observed in
advanced or secondary hypertension, is related to a greater adverse
prognosis (Izzard et al., 2006; Heagerty et al., 2010).
It is important to note that in essential hypertension the relationship
between BP and remodelling remains unclear.Whilst some studies sug-
gest that structural changes follow a change in BP and/or prolonged ar-
terial vasoconstriction (Bakker et al., 2002), there is evidence from
studies using genetically modiﬁed mice that structural changes may
precede the development of hypertension (Zacchigna et al., 2006).
Whilst studies on isolated arteries from animal models of hypertension
suggest that remodelling may be a consequence of reduced resistance
arterial distensibility (at least in the cerebral circulation) (Izzard et al.,
2006), others have shown increased distensibility (Laurant et al.,
1997). Thus, there is little to support changes in distensibilty of resis-
tance arteries being the primary driver for remodelling in all vascular
beds. Therefore, debate on this topic continues; hence, further under-
standing of how arterial remodelling may be initiated and progresses
in relation to a change in BP is important for elucidating the factors con-
tributing to the development and progression of high BP.
3.2. Arterial contractility and hypertension
The contractility of resistance arteries is important in setting periph-
eral vascular resistance, and thus BP. Whilst enhanced arterial constric-
tion will, in itself, increase vascular resistance, it appears that the major
consequence of altered levels of contractile activation in hypertension is
on arterial remodelling. Studies on isolated rat small arteries main-
tained in culture have shown that chronic vasoconstriction itself in-
duces eutrophic remodelling and that this remodelling is independent
of the vasoconstrictor stimulus (Bakker et al., 2000, 2002, 2004). Fur-
thermore, chronic in vivo infusion of vasoconstrictor stimuli in animals
has also been shown to induce remodelling (Eftekhari et al., 2007). En-
hanced contraction may occur as a result of changes in external stimuli
and/or due to underlying contractile mechanisms. Although elevated
sympathetic activity, increased sensitivity to vasoactive stimuli (Angus
et al., 1992) and increased myogenic tone (Izzard et al., 1996) have
been shown to be involved in the development of hypertension in
some vascular beds, such changes do not appear to persist when hyper-
tension is established (Izzard et al., 1996, 2006). There ismuch debate in
the literature aboutwhether structural changes amplify vasoconstrictor
responses (Wright & Angus, 1999; Folkow, 2000; Korner et al., 2000;
Izzard et al., 2002), hence the relationship between active tone and re-
modelling remains to be fully elucidated. Nevertheless, it is generally ac-
cepted that changes in contractility of some resistance arteries play a
key role in remodelling during the development of hypertension. In
support of this it has been shown that normalisation of vascular struc-
ture by anti-hypertensive therapies was independent of BP but was de-
pendent on vasodilatation (Mathiassen, Buus, et al., 2007a; Mulvany,
2012). Thus, it is important to further understand the mechanisms
which modulate resistance arterial contractility in both the developing
and sustained phases of hypertension.
Arterial tone is principally regulated via the contractile state of
VSMCs. This can be modulated by stimuli acting directly on the VSMCs
or by those acting on the vascular endothelium which lines the lumen
of blood vessels. The endotheliummodulates arterial tone by the release
of and/or stimulation of powerful vasodilating and vasoconstricting fac-
tors, principally nitric oxide (NO), prostacyclin and endothelium de-
rived hyperpolarising factor (Furchgott & Zawadzki, 1980; Mombouli
& Vanhoutte, 1999; Feletou & Vanhoutte, 2009). NO is a powerful vaso-
dilator and is synthesised via nitric oxide synthase (NOS) of which three
forms exist; endothelial NOS (eNOS) primarily from endothelial cells;
neuronal NOS (nNOS) which is expressed in peripheral nitrergic nerves
innervating smooth muscle and also reported in aortic VSMCs; and in-
ducible NOS (iNOS)—the source of which is not clear in the vasculature
((Forstermann et al., 1995; Furchgott & Zawadzki, 1980); H. (Schwarz
et al., 1999; Li et al., 2002)). NO induces dilation via activation of cyclic
guanosine monophosphate (cGMP)-mediated pathways (Waldman &
Murad, 1987; Bolotina et al., 1994; Ignarro, 2002). cGMP appears to be
important in BP regulation as global ablation of cGMP results in in-
creased conscious BP (Pfeifer et al., 1998).
Endothelial dysfunction has been reported in numerous disease
states including in hypertensive rodents and has also been proposed
to occur in old hypertensive patients (Fujii et al., 1992; Taddei et al.,
Fig. 1. Eutrophic remodelling of resistance arteries. Increased intraluminal pressure ( ) is
associated with cellular rearrangement, principally of VSMCs, resulting in a narrower
lumen diameter (L) and increased wall thickness (W) of the vessel.
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1997; Vanhoutte et al., 2005; Taguchi et al., 2015), however, this is not a
uniform ﬁnding (Li & Bukoski, 1993). Indeed, in some studies
endothelium-dependent relaxation of resistance arteries has been re-
ported to be preserved in hypertension by an NOS-dependent mecha-
nism (Kang et al., 2007). Other studies have shown that abnormal
endothelial function in small blood vessels does not predict cardiovas-
cular events in patients with essential hypertension (Rizzoni et al.,
2006) and indeed such dysfunction appears to be independent of vascu-
lar structural changes in hypertension (Rizzoni et al., 1998). There con-
tinues to be debate as to the role of the endothelium in the development
and progression of hypertension (Luscher, 1994), nevertheless, the en-
dothelium is an important modulator of vascular contractility and BP
which should not be ignored when developing new therapeutic targets
for hypertension.
3.3. Mechanisms controlling arterial contractility; role of intracellular free
calcium
It is ultimately the contractile state of vascular smoothmusclewhich
determines the level of vascular tone. As such, it is important to under-
stand the underpinning mechanisms which mediate smooth muscle
contractility.
The concentration of intracellular free calcium ([Ca2+]i) underpins
the modulation of VSMC contractility and thus arterial diameter and
vascular resistance. An increase in [Ca2+]i results in activation ofmyosin
light chain kinase (MLKC), subsequent phosphorylation of myosin, and
VSM contraction. Conversely, a fall in [Ca2+]i results in activation ofmy-
osin light chain phosphatase and dephosphorylation of myosin, hence
promoting arterial relaxation (Somlyo & Somlyo, 1994; Gollasch et al.,
2000; McCarron et al., 2006). [Ca2+]i levels are modulated by either in-
ﬂux/efﬂux across the plasmalemma and or release/sequestration into
intracellular calcium stores predominantly, but not exclusively, the sar-
coplasmic reticulum (SR). (Although a brief overviewof themainmech-
anisms is given below a detailed discussion of the mechanisms which
modulate calcium homeostasis in smooth muscle is beyond the scope
of this text and as such we direct the reader towards reviews of this
area for more information (Amberg & Navedo, 2013; Hill-Eubanks
et al., 2011; Kudryavtseva et al., 2013)). The relationship between
Ca2+ and contraction is, however, not straightforward and it is now ev-
ident that subcellular Ca2+ ﬂuxes and microdomains exist which may
differentially modulate contractile function (Gollasch et al., 2000;
McCarron et al., 2006).Whilst an increase in global [Ca2+]i promotes ar-
terial contraction, localised increases in Ca2+ may have different effects
on contraction. For example, in isolatedmyogenic cerebral arteries, local
increases in intracellular calcium following activation of ryanodine re-
ceptors on the SR cause arterial vasodilation via activation of Ca2+-acti-
vated potassium channels (Nelson et al., 1995). In contrast, in isolated
retinal arteries it has been shown that Ca2+ sparks can promote myo-
genic tone, most likely via summation to generate Ca2+ waves/oscilla-
tions (Tumelty et al., 2007; Kur et al., 2013). Although modulation of
the calcium sensitivity of the contractile apparatus can regulate VSMC
contractility (Kimura et al., 1996; Uehata et al., 1997; Andre et al.,
2014; Takeya et al., 2014) it is clear that regulating [Ca2+]i within
VSMCs plays a crucial role in regulating the contractile state of VSMCs,
and hence vascular resistance and thus BP. As such, factors whichmod-
ulate Ca2+ homeostasis in vascular smooth muscle are particularly at-
tractive therapeutic targets for BP reduction and potential reversal of
inward remodelling in resistance arteries.
Ca2+ inﬂux into VSMCs is principally driven by plasma membrane
voltage gated Ca2+ channels (VGCC), particularly L type Ca2+ channels.
Though, notably, increased [Ca2+]i can be promoted by activation of
Ca2+ release channels, including ryanodine receptors and inositol
1,4,5-trisphosphate receptors on the SR, and also via transient receptor
potential (TRP) channels (Jackson, 2000; Parekh & Putney, 2005; Earley
et al., 2007; Gonzalez-Cobos & Trebak, 2010). There is evidence to sug-
gest that high BP can modulate activation of calcium channels via
changes in their expression level or by affecting their functional ionic
conductance (Stekiel et al., 1986; Pesic et al., 2004). Such effects can ex-
acerbate vasoconstriction and elevate vascular resistance and BP; hence,
treatment strategies to reduce high BP have long involved the use of L-
type VGCC inhibitors (Sonkusare et al., 2006). Further, Ca2+ channel
blockers which dilate resistance arteries have been shown to reverse
eutrophic remodelling (Schiffrin, 2004; Agabiti-Rosei & Rizzoni, 2010).
Taken together this suggests that therapies which target intracellular
calciumhomeostasis areworthy of exploration. This should also include
investigation intomechanismswhich reduce levels of intracellular Ca2+
and could stimulate arterial dilation. Thesemechanisms include seques-
tration into intracellular stores, most notably into the SR via its Ca2+-
ATPase pump (SERCA), and via extrusion across the plasmamembrane.
The activity of SERCA is regulated by phospholamban (PLN); aortic con-
tractions from PLN-deﬁcient mice have been shown to be reduced, ef-
fects which were abolished by pharmacological SERCA inhibitors (Lalli
et al., 1997; Oloizia & Paul, 2008). Thus, modulation of mechanisms
which decrease cytoplasmic Ca2+ can modulate arterial contractility
and may thus be a potential target for reduction of BP. Ca2+ can be ex-
truded out of VSMCs by two different Ca2+ transporting systems, the
Na+/Ca2+ exchanger (NCX), predominantly type 1 (NCX1) (Quednau
et al., 1997), and plasma membrane calcium ATPase type 1 or 4
(PMCA1, PMCA4) (Oloizia & Paul, 2008). In the heart, NCX plays a
major role in Ca2+ extrusion extruding one Ca2+ out of the cell in ex-
change for three Na+ ions (Bers, 2000). In VSMCs, however, it is bi-
directional and canmodulate Ca2+ efﬂux or inﬂux depending on the rel-
ative concentrations of Ca2+ and Na+ (Blaustein & Lederer, 1999) and
its role in Ca2+ extrusion has been questioned (Kamishima &
McCarron, 1998). Indeed smooth muscle-speciﬁc genetic ablation of
NCX1 lowers BP (Zhang et al., 2010; Zhao et al., 2011), whilst, converse-
ly, mice overexpressing NCX1 in smooth muscle display increased BP
(Blaustein & Lederer, 1999; Iwamoto et al., 2004); effects not consistent
with a predominant role in Ca2+ extrusion. Currently there is little
known about the speciﬁc contribution of PMCAs to Ca2+ efﬂux in
VSM, but in bladder and myometrial smooth muscle extrusion by this
route has been reported to contribute approximately 30% and 70% of
total calcium efﬂux respectively (Matthew et al., 2004; Liu et al.,
2006). Therefore, a greater understanding of the role of PMCAs in the
microcirculation is important for further understanding of the regula-
tion of BP and how it might be pharmacologically modulated.
4. Plasma membrane calcium ATPases
PMCAs are 10 transmembrane domainATP-dependent pumps of the
P-type family. Four separate PMCA proteins, 1–4, are evident in mam-
mals with each being expressed from its respective gene (i.e. ATP2B1
gene encodes PMCA1 protein). Numerous splice variants of each gene
have been found to be functionally expressed, with the possibility that
over 30 variants can be generated (Keeton et al., 1993; Di Leva et al.,
2008). The N and C termini of PMCA are both intracellular, with the
far longer C terminus containing regulatory domain binding sites and
PDZ domains physically linking to interacting partners (James et al.,
1988; Kessler et al., 1992; Hofmann et al., 1993; Di Leva et al., 2008). Ex-
tracellular loops are believed to be of minimal length (Di Leva et al.,
2008), Fig. 2.
PMCA1 is ubiquitously expressed in humans; ablation of PMCA1 is
embryonically lethal early inmousedevelopment leading to the sugges-
tion that the protein has a ‘housekeeping’ or developmental role
(Okunade et al., 2004; Brini, 2009; Kenyon et al., 2010). PMCA4 is also
present in most cell types, but its function may be more tissue speciﬁc
than PMCA1 (Schuh et al., 2004). Tissue expression of PMCA2 and
PMCA3 is far more limited, with theirmain functional role being in neu-
ronal cells and the ear (Kozel et al., 1998). PMCA1 and PMCA4 are both
present in the vasculature and thus have the potential to contribute to
vascular structure and function.
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4.1. Expression of plasma membrane calcium ATPases in the vasculature
PMCAs have been shown to be present in both VSMCs and endothe-
lial cells and can thus potentiate vascular function via actions on either
of these cells types. PMCA1 RNA has been detected in pig aortic smooth
muscle and endothelial cells (Pande et al., 2006), whilst mRNA for
PMCA1 has also been detected in rat cultured aortic VSMCs (Sasamura
et al., 2002). At the protein level, PMCA1 is present in VSMCs from
mouse aorta (Kobayashi et al., 2012), as well as in endothelial cells
from the pig coronary artery (Szewczyk et al., 2007).
PMCA4 mRNA has been detected in endothelial and VSMCs of por-
cine aorta (Szewczyk et al., 2007), in VSMCs from mouse carotid artery
(Afroze et al., 2014), and was shown as the most prominent PMCA
mRNA transcript in mouse whole aorta (Okunade et al., 2004). PMCA4
protein expression has been reported in a mouse VSMC line (Afroze
et al., 2003) and in isolated murine aortic VSMCs (Momen et al., 2014).
Although it is clear that both PMCA1 and PMCA4 are present in the
vasculature their relative expression is difﬁcult to quantify. However,
Pande and colleagues have suggested that PMCA4 is the dominant
form in pig aortic VSMCs (Pande et al., 2006). In contrast, others have
shown that mRNA for PMCA1 is more prevalent than that for PMCA4
in rat cultured aortic VSMCs, with PMCA4 transcripts suggested to be
at only a quarter of the level of those for PMCA1 (Sasamura et al.,
2002). In porcine aortic endothelial cells PMCA1 RNA has been shown
to be detectable at a higher level than PMCA4 transcripts (Pande et al.,
2006; Szewczyk et al., 2007). Thus, the vascular expression of PMCA1
and 4may be species speciﬁc, with furtherwork being required to clear-
ly determine the relative expression of PMCA1 and PMCA4 in VSMCs
and endothelial cells, particularly in resistance arteries.
5. Plasma membrane calcium ATPase 1, arterial contractility and
blood pressure regulation
Although multiple factors underpin the development of essential
hypertension, heritability of 30–60% may combine with other risk fac-
tors to potentiate disease development (Miall & Oldham, 1963;
Kupper et al., 2005). As such, there has been a long standing search for
genetic components of hypertension. Advances in genome sequencing
technology, determining quantitative trait loci by assessing single nu-
cleotide polymorphisms (SNPs) in disease relative to control cohorts,
have, relatively recently, highlighted genomic regions which may con-
tribute as single factors in BP regulation. Crucially, a genomic region
containing ATP2B1, which encodes for PMCA1, has been identiﬁed as
having a very strong associationwith BP variance and/orwith hyperten-
sive disease in different human population groups (Cho et al., 2009;
Levy et al., 2009; Hong et al., 2010; Takeuchi et al., 2010; Johnson
et al., 2011). Importantly, SNPs associating ATP2B1 with BP have
attained genome wide signiﬁcance in replication analyses in multiple
different ethnic groups and have shown a consistently high level of ge-
netic association (Tabara et al., 2010; Miyaki et al., 2012; Xi et al., 2012;
Ganesh et al., 2013; Wang et al., 2013). SNPs relating to ATP2B1 in a
Japanese cohort were found to give an odds ratio of 1.17 to 1.31 for hy-
pertension (Tabara et al., 2010), a very similar level of risk as reported
by other large scale GWAS. More recently ATP2B1 has been genetically
linkedwith pulse pressure (Kelly et al., 2013) and to coronary artery cal-
ciﬁcation andmyocardial infarction in chronic kidney disease (Ferguson
et al., 2013), further substantiating a possible genetic link to cardiovas-
cular function. How ATP2B1 may be associated with cardiovascular
function cannot be directly determined by GWAS. Detection of SNPs as-
sociatedwith hypertension in the promoter region of ATP2b1 (Cho et al.,
2009; Tabara et al., 2010) could suggest that it is modulation of gene ex-
pression which may drive a BP phenotype. Furthermore, ATP2b1mRNA
expression has been reported to be reduced in human umbilical artery
smooth muscle cells from people carrying risk alleles as determined
by GWAS (Tabara et al., 2010). However, with ATP2b1 genomic regions
also having been shown to be associated with hyperlipidemia and dia-
betes (Heo et al., 2014), the potential role of PMCA1 in BP regulation
may additionally be due to indirect effects on metabolism.
Thus, there is accumulating evidence to support an important role
for ATP2b1 in BP regulation. It should, however, be noted that genome
linkage analysis is correlative and does not deﬁnitively demonstrate a
cause-effect relationship between a genomic region and a BP phenotype
(Deng, 2007). Therefore, it has been paramount to physiologically link
PMCA1 to a BP phenotype to clearly show the protein can indeed func-
tionally regulate BP.
Geneticallymodulated animalmodels arewidely used to directly in-
vestigate the effect of changes in gene and protein expression on phys-
iological function. Global ablation of Atp2b1 in mice is embryonically
lethal early in development, between 3.5 and 8.5 days of pregnancy,
suggesting an important role for PMCA1 in development (Okunade
et al., 2004; Shaheen, 2012). PMCA1 has been proposed to have a role
in BP regulation as mice bred to be globally heterozygous for Atp2b1,
whilst indeed viable, exhibit elevated BP (Fujiwara et al., 2014). Elevat-
ed peripheral BP was also reported in mice following injection of siRNA
constructs to block production of PMCA1 protein (Shin et al., 2013).
Studies using mice with VSMC speciﬁc deletion of PMCA1, generated
using the Cre-loxP system, support a speciﬁc role in the vasculature
for Atp2b1. Whilst the gross phenotype and survival of these mice
were unaffected, they did exhibit signiﬁcantly elevated systolic BP
(Kobayashi et al., 2012).
Femoral arteries frommice devoid of VSM PMCA1 protein exhibited
enhanced contractility to phenylephrine (Kobayashi et al., 2012), whilst
studies using heterozygous Atpb1mice demonstrated both an increased
contractility to phenylephrine and a reduced endothelium-dependent
dilation to acetylcholine from isolated abdominal aorta vascular rings
(Fujiwara et al., 2014). Similarly, elevated BP following silencing of
Atp2b1, has been associated with enhanced isolated small artery con-
tractility to phenylephrine and increased myogenic responsiveness
(Shin et al., 2013). Importantly, siRNA knockdown of Atp2b1 has been
associated with an increased media:lumen ratio in mesenteric resis-
tance arteries, characteristic of essential hypertension (Shin et al.,
2013). Thus there is now substantial evidence to support an involve-
ment of PMCA1 in BP regulation, in part at least, via effects on the struc-
ture and function of small arteries.
Fig. 2. Schematic representation of the transmembrane positioning of the PMCA protein.
The 10 transmembrane domain structure of mammalian PMCA. N and C termini for
both PMCA1 and 4 are intracellular. ATP binding to the catalytic domain (Φ) promotes
Ca2+ efﬂux, which is modulated by the autoinhibitory Ca2+-calmodulin binding domain
(CaM).
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The mechanisms whereby modiﬁcations in the expression of
Atp2b1/PMCA1 canmodulate arterial structure and function still require
further elucidation; however, as PMCA1 is a Ca2+ extrusion pump one
potential way is clearly by modulation of global [Ca2+]i. In support of
this, cultured VSMCs from smooth muscle-speciﬁc PMCA1 deleted
mice exhibited elevated levels of basal [Ca2+]i and also in response to
phenylephrine stimulation (Kobayashi et al., 2012). However, evidence
from heterozygous PMCA1 mice shows that PMCA1 can also modulate
arterial tone via effects on NO, effects attributed to a reduced phosphor-
ylation of eNOS (residue Ser-1177) and production of NO (Fujiwara
et al., 2014). Endothelial cells from heterozygous Atp2b1 mice exhibit
reduced expression of eNOS, with no signiﬁcant difference in nNOS ex-
pression being reported (Fujiwara et al., 2014). A functional interaction
between PMCA1 and eNOS has been demonstrated in human endothe-
lial cells, however, in contrast to animal studies, PMCA1 appears to be a
negative regulator of eNOS primarily via increased phosphorylation of
Thr-495 of eNOS; Thr-495 being an inhibitory residue (Holton
et al., 2010). There is clearly a need for further study to elucidate
the effects of PMCA1 on eNOS activity, endothelial function and
subsequent effects on the resistance vasculature and on BP. Also It
should be noted that the effects of PMCA1 on other endothelial fac-
tors also needs to be established especially as NO generally plays a
smaller role in resistance arteries than it does in large arteries
(Urakami-Harasawa et al., 1997).
Thus, there is now increasing evidence for a clear link between
Atp2b1/PMCA1 and BP, effects which can be modulated by changes in
arterial contractility. Effects of PMCA1 in VSMCs and on global [Ca2+]i
are consistent with a major role for PMCA1 in Ca2+ extrusion, whilst
howPMCA1maybe involved in arterial remodelling requires further in-
vestigation. Further work is clearly required to elucidate the different
ways in which PMCA1 may modulate arterial contraction. To date,
data on only one relatively selective inhibitor of PMCA1, the small pep-
tide caloxin 1b3, has been published (Szewczyk et al., 2010). Caloxin
1b3 has been reported to be selective for PMCA1 in rabbit duodenalmu-
cosa and pig coronary artery endothelial cells, and has been shown to
increase [Ca2+]i in these endothelial cells (Szewczyk et al., 2010). How-
ever, the inﬂuence of caloxin 1b3 on arterial contractility and BP re-
mains to be clearly determined. Nevertheless, the strong clinical
evidence of an association between ATP2B1 and BP, coupledwith exper-
imental studies directly linking changes in PMCA1 expression to in-
creases in resistance arterial contractility and increased BP, make
PMCA1 a very attractive potential therapeutic target which warrants
further exploration.
6. Plasmamembrane calcium ATPase 4 in blood pressure regulation
Although there is a wealth of clinical evidence suggesting a role for
PMCA1 in BP regulation there is also substantial evidence from experi-
mental studies which show that changes in the expression of PMCA4
can also modulate arterial contractility and BP. To date, two investiga-
tive approaches have been taken; 1) studies employing transgenic over-
expression of PMCA4 in vivo and 2) pharmacological inhibition of
PMCA4.
6.1. Transgenic expression of plasma membrane calcium ATPase 4
Studies conducted by Gros and colleagues and Schuh and colleagues
over a decade ago provided the ﬁrst evidence that PMCAs canmodulate
arterial contractility and BP (Gros et al., 2003; Schuh et al., 2003). Both
groups generated transgenic mice overexpressing human PMCA4b, ei-
ther under control of vascular-speciﬁc SM22α promoter or
doxycycline-induced overexpression in smooth muscle, (Gros et al.,
2003; Schuh et al., 2003). Perhaps surprisingly, both transgenic mouse
models exhibited an increase in BP. The elevated BP was accompanied
by enhanced aortic contraction to K+-mediated membrane
depolarisation (Schuh et al., 2003), plus heightened myogenic tone
and elevated response to adrenergic stimulation in mesenteric arteries
(Gros et al., 2003). These effects are not consistent with PMCA4 acting
as a major contributor to removal and modulation of global [Ca2+]i. In-
deed, it has been shown that basal arterial VSMC [Ca2+]i was compara-
ble in both PMCA4 overexpressing and control mice (Gros et al., 2003).
The changes in arterial contractility in both animal models were
prevented by inhibition of nNOS pointing to negative regulation of
nNOS activity by PMCA4 (Gros et al., 2003; Schuh et al., 2003). Previous
studies in human endothelial cells have shown that PMCA4 interacts
with eNOS leading to increased phosphorylation at Thr-495 and re-
duced enzymatic activity (Holton et al., 2010). However, in aortae at
least, endothelium-dependent relaxation to acetylcholinewas unaffect-
ed by overexpression of PMCA4 (Schuh et al., 2003). Although it is im-
portant that the effects of PMCA4 overexpression on endothelial
function in resistance arteries are investigated, results so far, together
with the fact that NO plays a lesser role in endothelium-dependent dila-
tion in resistance arteries when compared to large arteries (Urakami-
Harasawa et al., 1997), suggest that the endothelium does not play a
major role in the effects of PMCA4 onmodulation of arterial contraction
and BP. To date, no published studies have looked at the effects of genet-
ic ablation of Atp2b4 (for PMCA4 protein) on resistance arterial struc-
ture or function.
It is now evident that PMCA4 has a major role in signal transduction
in a number of excitable cells. In isolated molecular experiments,
cardiomyocytes and whole heart tissue PMCA4 functionally associate
with calcineurin (Buch et al., 2005), Ras-associated factor 1 (Armesilla
et al., 2004),α1-syntrophin (Williams et al., 2006) and nNOS, the latter
via interaction with the PDZ domain on PMCA4 (Schuh et al., 2001;
Oceandy et al., 2007; Duan et al., 2013). In blood vessels any such asso-
ciation of PMCA4 and nNOS clearly appears to be of relevance to the reg-
ulation of arterial contractility. It is well known that NO can inﬂuence
contractility of peripheral blood vessels, and it is becomingmore appar-
ent that vascular NO production is not just mediated by eNOS but also
via nNOS activity (Kaley et al., 1992; Buchwalow et al., 2002; Webb
et al., 2006). nNOS-mediated NO production in a cellular assay has
been shown to be signiﬁcantly reduced when the enzyme is tethered
as part of a macromolecular complex including PMCA4, conﬁrming
that PMCA4 is a negative regulator of nNOS activity (Schuh et al.,
2004). The exact way in which PMCA4 modulates vascular nNOS activ-
ity is unknown, but nNOS activity is calcium/calmodulin dependent and
a role for PMCA4 in regulating localised Ca2+ concentrations in amicro-
domain has been suggested (Cartwright et al., 2007).More recent inves-
tigation of the role of PMCA4 in cardiac signalling has supported this
supposition, pointing to PMCA4 having an important role as a structural
molecule in the heart (Oceandy et al., 2007; Mohamed et al., 2011).
Overexpression of PMCA4 in arterial smooth muscle has been shown
to signiﬁcantly reduce nNOS activity (Gros et al., 2003). Hence, reduced
production of vasodilatory NO has been proposed in explanation for el-
evated BP observed in PMCA4 overexpressing mice (Gros et al., 2003;
Schuh et al., 2003). Thus, studies from transgenic overexpressing mice
suggest that PMCA4 is a powerful modulator of BP and that changes in
resistance arterial contractility, as a result of negative regulation of
nNOS by PMCA, are likely contributors to this. However, a different
role for PMCA4 in the vasculature has been proposed following a differ-
ent experimental approach: that of pharmacological inhibition of
PMCA4 using caloxin peptides (Chaudhary et al., 2001).
6.2. Pharmacological modulation of plasma membrane calcium ATPase 4
activity
The role of PMCA4 in the vasculature has been further assessed phar-
macologically by using caloxin peptides, which have been designed to
inhibit the protein's ability to pump Ca2+. A number of caloxin com-
pounds have been designed, with screens against PMCA4 identifying
caloxin 1b1 as an inhibitor of PMCA4 (Ki = 46 ± 5 μM compared
Ki = 105 ± 11 μM for PMCA1) (Pande et al., 2006). By binding to the
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ﬁrst extracellular domain of PMCA4 it is proposed that caloxin 1b1 in-
hibits Ca2+ ﬂux non-competitively by blocking/altering the required
conformational change in the protein which occurs with the binding
of ATP (Holmes et al., 2003; Pande et al., 2006).
Although the effects of caloxin 1b1 on BP have not been investi-
gated, acute application has been shown to increase contraction of
rat aortic rings in response to agonist stimulation (Pande et al.,
2006). Furthermore, caloxin 1b1 has been shown to potentiate in-
creased [Ca2+]i, promoted by Ca2+ ionophore application in cultured
arterial VSMCs derived from porcine aorta (Pande et al., 2006). Sub-
sequently caloxin 1c2 (Ki = 2.3 ± 0.3 μM), a more selective PMCA4
inhibitor with ten-fold greater selectivity for PMCA4 over other
PMCAs, has been shown to increase the basal tone of isolated coro-
nary arteries and the force of their contraction compared to control
tissues at low extracellular Ca2+ levels ([Ca2+]o) (b1.6 mM) whilst
in the presence of inhibition of NCX and SERCA (Pande et al., 2008).
Thus, available evidence to date as to the effects of caloxins corre-
lates with the expectation that inhibiting a Ca2+ extrusion pump
would elevate [Ca2+]i in PMCA4 expressing VSMCs and contribute
to augmented vascular contractility and BP. It is however important
to highlight that previous studies have only explored the effects of
caloxins on larger arteries, namely coronary arteries and the aorta,
which do not make signiﬁcant contributions to overall vascular resis-
tance and BP (Pande et al., 2006, 2008). There is thus a pressing need
to explore the effects of PMCA4 inhibitors on resistance arteries. The
effects of PMCA4 inhibition on endothelium function also need to be
elucidated.
As previously discussed, regulation of [Ca2+]i in vascular cells is im-
portant for determining arterial tone and vessel contractility.Whilst the
effects of caloxins point to a role for PMCA4 in BP regulation, inhibiting
the Ca2+ extrusion pumping capability of PMCA4 seems inappropriate
for a novel direct anti-hypertensive drug. However, other factors relat-
ing to tissue perfusion may also be considered, as PMCA4 has been pro-
posed as an endogenous regulator of processes leading to angiogenesis
(Baggott et al., 2014). Hence, there is a requirement for further under-
standing of the effects of inhibiting PMCA4 and also development of
new drugs against the protein.
We have recently identiﬁed aurintricarboxylic acid (ATA) as a novel
inhibitor of PMCA4, being capable of fully inhibiting PMCA4 at 1 μM
(Mohamed et al., 2013). In vitro, ATA was found to have a dose depen-
dent effect on PMCA4 (IC50 approximately 150nM), and have only a
very minor effect on PMCA1 and SERCA with no inhibitory effect on
the Na+/K+ ATPase (Mohamed et al., 2013). Thus, we propose that
ATA, with its high level of selectivity over other PMCA isoforms and P-
type ATPases, will be a useful tool to further elucidate the effects of
PMCA4 in regulating resistance arterial contractility and BP. ATA, how-
ever, modulates a variety of different cellular processes. For example,
it has been shown to act as a nuclease inhibitor for isolation of nucleic
acids (Hallick et al., 1977; Gonzalez et al., 1980), as an inhibitor of the
RISC complex hence blocking micro RNA synthesis (Tan et al., 2012)
and as a potential inhibitor of glutamate dehydrogenase (Li et al.,
2007). It has also been shown to protect cells from human
complement-mediated lysis, to reduce tube formation by endothelial
cells (Lipo et al., 2013) and to have neuroprotective effects, possibly
via inhibition of complement factors of the innate immune system
(Lee et al., 2012) or via promoting receptor tyrosine kinase signalling
(Okada & Koizumi, 1995). Whether these effects are due, in part at
least, to the effects of ATA on PMCA4 has largely not been considered.
Whilst multiple actions of ATA may limit its use as a therapeutic
cardiovascular strategy, we have previously discussed that complete
inhibition of PMCA4 can be achieved at 1 μM, a concentration approxi-
mately 100 fold lower than which effects on other targets have been re-
ported to occur (Mohamed et al., 2013). Nevertheless, the development
of more speciﬁc pharmacological tools for PMCA4 is essential to further
our understanding of the effects of PMCA4 on resistance arterial
contraction and BP.
In summary, available evidence to date suggests that both over-
expression and inhibition of PMCA4 increase arterial contractility
whichmay, in turn, increase BP. Whilst it is clear that PMCA4 affects ar-
terial contractility and BP, these effects, and indeed the underpinning
mechanisms, may be complex and variable andmany questions remain
unanswered. Studies to date suggest that PMCA4 may modulate bulk
Ca2+ homeostasis, nNOS signalling (Pande et al., 2006, 2008) and
eNOS activity (Holton et al., 2010). It is noteworthy that recent studies
investigating PMCA4 in the cell cycle have concluded that its role is re-
lated both to its activity and its scaffolding effects (Afroze et al.,
2014)—this has been demonstrated using two mouse models, one in
which there is a complete lack of PMCA4 protein, whilst the other has
a mutant, non-functioning PMCA4 (Okunade et al., 2004; Schuh et al.,
2004). The availability of the PMCA4knockoutmouse affords the oppor-
tunity for investigation of the effects of PMCA4 ablation on BP and arte-
rial contractility. For any clear consensus on the role of PMCA4 in
vascular contractility, assessment of a different class of PMCA4 inhibi-
tors, with increased speciﬁcity, needs to be made (Pande et al., 2006,
2008; Szewczyk et al., 2008). Indeed, the recent identiﬁcation of ATA
as a highly selective PMCA4 inhibitor (Mohamed et al., 2013) has ad-
vanced the pharmacology in thisﬁeld, andmay prove to be a highly use-
ful tool in deﬁning the contribution of PMAC4 to BP regulation.
7. Treatment strategies and future directions
In UK clinical practice it is currently recommended that for people
aged 55 or older treatment for hypertension focuses on the use of calci-
um channel blockers as a ﬁrst step (NICE, 2011). This highlights the fun-
damental role Ca2+ has for appropriate cardiovascular function.
Calcium channel blockers act to inhibit Ca2+ inﬂux into cells; Ca2+ ef-
ﬂux pathways have not previously been considered for the develop-
ment of BP lowering pharmacology. The resistance vasculature is an
important target for anti-hypertensive therapies and indeed elevated
cardiovascular risk remains despite a reduction of BP if inward remodel-
ling of the microcirculation is not reversed (Buus et al., 2013). Calcium
channel blockers, and indeed other anti-hypertensive therapies (ACE
inhibitors, angiotensin II receptor blockers) have beneﬁcial effects on
both BP and small artery structure, others, includingdiuretics, have little
effect on arterial structure (Schiffrin, 2004; Agabiti-Rosei & Rizzoni,
2010). Given the relation to cardiovascular risk, regression of small ar-
tery remodelling is an important goal for the development of new
anti-hypertensive therapies alongside BP reduction. This may be inﬂu-
enced by changes in resistance arterial contractility (Izzard et al., 1996).
PMCA1 and PMCA4 are the two key PMCAs expressed in cardiovas-
cular tissues.Withmodulation of both BP and arterial contractility being
demonstrated with changes in the expression and/or activity of both
PMCA1 (Kobayashi et al., 2012; Shin et al., 2013), and PMCA4 (Gros
et al., 2003; Schuh et al., 2003), both have the potential to be new phar-
maceutical targets for BP control. The association between ATP2B1 var-
iants and BP variance and/or hypertension in human subjects (Cho
et al., 2009; Levy et al., 2009; Hong et al., 2010; Takeuchi et al., 2010;
Johnson et al., 2011) suggests that PMCA1 at least may play an impor-
tant role in the genetic susceptibility to hypertension. Coupled with
the recent observation reporting a genetic link between ATP2B1 and re-
sistant hypertension (Fontana et al., 2014), there is thus increasing evi-
dence to support PMCA1 as an attractive target for BP and resistance
arterial modulation. It is worth noting that whilst effects of PMCA1 on
modulation of BP, arterial structure and intracellular calcium have
been demonstrated (Kobayashi et al., 2012) there remains a clear
need for investigation into the effects of the protein on resistance arte-
rial remodelling. Equally, the effects of PMCA1oneNOSand on endothe-
lial function need elucidating. Studies to date suggest that PMCA1
expression/activity is inversely correlatedwith BP suggestive that a spe-
ciﬁc activator of the pump would need to be developed to reduce BP.
Whilst development of these would undoubtedly be challenging, and
remains a concept rather than being actively pursued as a therapeutic
29R. Little et al. / Pharmacology & Therapeutics 159 (2016) 23–34
strategy, a number of natural PMCA activators have been identiﬁed
which would help inform work in this area (Lopreiato et al., 2014).
PMCA activity has been suggested to be increased by acidic phospho-
lipids (Filomatori & Rega, 2003; Cura et al., 2008). However,
PMCAs are not speciﬁcally activated by such mechanisms as phos-
phatidylinositol, and other similar molecules, can also modulate other
calcium channels (Kim et al., 2015; Mori et al., 2015). Further, whilst
calmodulin binds to an intracellular domain, relieving the auto-
inhibition on Ca2+ ﬂux as a physiological process for PMCA activation
(Fig. 2), it too has actions on other channels, negating it as a target for
speciﬁcally activating PMCA1 (Choi et al., 2014; Alli et al., 2015).
Studies on PMCA4 overexpressing mice which demonstrate an in-
crease in BP (Gros et al., 2003; Schuh et al., 2003) suggest that develop-
ment of a pharmacological inhibitor of the protein might be an effective
anti-hypertensive therapy. However, previous studies using caloxins to
inhibit PMCA4 do not support this as such treatment induces an in-
crease in arterial contractility (Pande et al., 2006). Whilst these studies
potentially reveal different mechanisms whereby PMCA4 may
modulate contractility there is a clear need for assessment of the effects
of caloxins on resistance arteries and indeed the effect of more speciﬁc
inhibitors of PMCA4 on BP and on arterial structure and function. Indeed
a more speciﬁc inhibitor of PMCA4 has now been identiﬁed (Mohamed
et al., 2013)whichwill provide a useful pharmacological tool for further
investigating the effects of PMCA4 inhibition on vascular function and
on BP. The experimental approaches used to assess the role played by
PMCA1 and PMCA4 in BP regulation and in the vasculature, and current
knowledge relating to these is shown in Fig. 3. Furthermolecular under-
standing of the actions of PMCAs, at a basic science level, is required be-
fore new clinical agents may be developed. Use of new pharmacological
tools may highlight possible interventional routes, and indeed may be
translated into future new antihypertensive therapies.
In summary, whilst strategies to reduce weight and promote a
healthy lifestyle do, and will continue to, successfully reduce BP in
some patients, new pharmacological therapies are required to treat
chronic hypertension which still persists in signiﬁcant numbers of indi-
viduals. Although further work is required to elucidate the precise
Fig. 3. Outline of experimental approaches assessing how PMCA1 (A.) and PMCA4 (B.) may have a role in vascular function and BP regulation.
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role(s) of PMCA1 and 4 in the development and progression of hyper-
tension the clear association between PMCA and BP in humans coupled
with experimental evidence supporting a direct role for PMCAs inmod-
ulation of arterial function and BP highlights PMCA as a potential new
target for the treatment and management of hypertension. This war-
rants further investigation.
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